Drugmakers are developing more biologic drugs and building new plants to manufacture them. And given that those plants all need filtration systems, analysts say it is no wonder that Pall would become a buyout prize. The Port Washington, NY-based company is being scooped up in $13.8 billion deal that rivals those orchestrated by some of its pharma clients.
With its largest acquisition ever, of filtration and purification system maker Pall for $13.8 billion, Danaher decided it had the ammunition to break itself into two publicly traded companies. The company's life science and technology units will retain the name Danaher, while a smaller company consisting of Danaher's diverse industrial businesses will be formed in late-2016.
WuXi PharmaTech, China's largest CRO, is considering an offer that would take it private at a sizable premium, forming a committee of independent advisers as it plots its next move.
As Baxter gears up to spin off its biopharma unit into new company Baxalta, it wants to make sure the new pharma has enough revenue to rely on. And to do that, it's bulking up.
As pharma companies jump left and right at dealmaking opportunities, GlaxoSmithKline CEO Andrew Witty is scratching his head.
CAR-T contender Juno Therapeutics is settling in for the long haul in a race to commercialize new immunotherapies for cancer, buying up a European biotech to firm up its process on the way to late-stage development.
Continuing a deal spree aimed at beefing up a weak pipeline, Pfizer has agreed to pay $87.5 million for a stake in the Dutch biotech AM-Pharma along with an option to buy the biotech. And there's another $512.5 million on the table should Pfizer exercise its option, with the deal hinging on the biotech's successful completion of a Phase II study of a new treatment for acute kidney injury (AKI) related to sepsis.
So far, Perrigo hasn't seemed too keen on selling itself to generics giant Mylan. It's rejected the U.S. drugmaker three times. But word has it that Perrigo tried to link arms with another generics giant on the block--and that's Mylan suitor Teva.
Mylan Chairman Robert Coury has said more than once that Mylan isn't interested in selling itself to Teva. A deal for Mylan to buy its pursuer, though? That's a different story.
Debiotech has gained an option with Oregon-based iSense CGM to acquire exclusive rights to use its continuous glucose monitoring technology with patch insulin pumps for diabetes treatment. The companies expect that the integration of Debiotech's Jewel Pump with the iSense continuous glucose monitor technology could lead to the creation of an accurate artificial pancreas--a device that continuously measures insulin levels and then automatically dispenses insulin accordingly in response.